Stephens analyst Sudan Loganathan raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $40 from $33 and keeps an Overweight rating on the shares. Following Q4 results and guidance, the firm raised its FY25 and FY26 EPS estimates to $1.76 and $2.27 from $1.60 and $1.67, respectively.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals Reports Record 2024 Financial Results
- Catalyst Pharmaceuticals Reports Strong Growth Amid Challenges
- Closing Bell Movers: Snowflake up 11%, Nvidia little changed after earnings
- Catalyst Pharmaceuticals reports Q4 EPS 70c, consensus 55c
- Catalyst Pharmaceuticals sees FY25 revenue $545M-$565M, consensus $558.08M